이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Novo Nordisk 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Lars Jorgensen

최고 경영자

DKK 60.1m

총 보상

CEO 급여 비율	28.5%
CEO 임기	6.9yrs
CEO 소유권	n/a
경영진 평균 재임 기간	2.8yrs
이사회 평균 재임 기간	5.8yrs

최근 관리 업데이트

업데이트 없음

Recent updates

CEO 보상 분석

Lars Jorgensen 의 보수는 Novo Nordisk 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

보상 대 시장: Lars 의 총 보상 ($USD 8.70M )은 Swiss 시장( $USD 5.58M ).

보상과 수익: Lars 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Lars Jorgensen (57 yo)

6.9yrs

테뉴어

DKK 60,100,000

보상

Mr. Lars Fruergaard Jorgensen has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member of Management Board. Mr. Jorgensen served as Deputy Chair of the...

리더십 팀

이름	위치	테뉴어	보상	소유권
Lars Jorgensen	President	6.9yrs	DKK 60.10m	데이터 없음
Karsten Knudsen	Executive VP	5.8yrs	DKK 21.50m	데이터 없음
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.0014% CHF 5.4m
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	0.000070% CHF 271.8k
Martin Lange	Executive VP of Development & Member of the Management Board	2.9yrs	DKK 20.90m	데이터 없음
Marcus Schindler	EVP of Research & Early Development	2.8yrs	DKK 20.90m	데이터 없음
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	데이터 없음	데이터 없음
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	데이터 없음	데이터 없음
Ludovic Helfgott	Executive VP	no data	데이터 없음	데이터 없음
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	less than a year	데이터 없음	데이터 없음
David Moore	Executive VP of Corporate Development & Member of Management Board	less than a year	데이터 없음	데이터 없음
Daniel Bohsen	CVP & Head of Investor Relations	no data	데이터 없음	데이터 없음

2.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: NOVOB 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sylvie Gregoire	Independent Director	8.8yrs	DKK 1.80m	데이터 없음
Helge Lund	Independent Chairman of the Board	6.8yrs	DKK 3.10m	데이터 없음
Henrik Poulsen	Vice Chairman of the Board	2.8yrs	DKK 2.00m	데이터 없음
Laurence Debroux	Independent Director	4.8yrs	DKK 2.00m	데이터 없음
Martin MacKay	Independent Director	5.8yrs	DKK 1.70m	데이터 없음
Andreas Fibig	Independent Director	5.8yrs	DKK 1.40m	데이터 없음
Kasim Kutay	Non-Independent Director	6.8yrs	DKK 1.20m	데이터 없음
Christina Law	Independent Director	1.8yrs	DKK 1.30m	데이터 없음
Liselotte Hyveled	Employee Representative Director	1.8yrs	DKK 800.00k	데이터 없음
Mette Jensen	Employee Non-Independent Representative Director	5.8yrs	DKK 1.20m	데이터 없음
Thomas Rantzau	Employee Representative Non-Independent Director	5.9yrs	DKK 1.00m	데이터 없음
Elisabeth Christensen	Employee Representative Director	1.8yrs	DKK 800.00k	데이터 없음

5.8yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: NOVOB 의 이사회는 경험(평균 재직 기간 5.8 년)으로 간주됩니다.

Novo Nordisk 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Recent updates

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

New minor risk - Shareholder dilution

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Now 21% undervalued

Second quarter 2023 earnings released: EPS: kr.8.65 (vs kr.5.87 in 2Q 2022)

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

Now 20% undervalued after recent price drop

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

First quarter 2023 earnings released: EPS: kr.8.81 (vs kr.6.24 in 1Q 2022)

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령